AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10691219 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurolytic celiac plexus block (NCPB) with bupivacaine followed by neurolysis during fluoroscopic control
Number of subjects: 50
Study 10691219 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurolytic celiac plexus block (NCPB)
Number of subjects: 50
Study 10691219 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated retrocrural neurolysis
Number of subjects: 50
Study 9347368 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopexamine (up to 2.0 micrograms/kg per min)
Number of subjects: 70
Study 9347368 — intervention group
Group type: COMPARATOR
Intervention: Dopamine (up to 6.0 micrograms/kg per min)
Number of subjects: 70
Study 9347368 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopexamine
Number of subjects: 70
Study 7910083 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy (group A)
Number of subjects: 101
Study 7910083 — intervention group
Group type: COMPARATOR
Intervention: Open cholecystectomy (group B)
Number of subjects: 101
Study 3723213 — intervention group
Group type: EXPERIMENTAL
Intervention: Vapor from carbonless forms
Number of subjects: 30
Study 3723213 — intervention group
Group type: COMPARATOR
Intervention: Bond paper (control)
Number of subjects: 30
Study 30614136 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT emphasizing exercise during behavioural activation (CBT‐E)
Number of subjects: 98
Study 30614136 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT emphasizing pleasurable low‐energy activities (CBT‐C)
Number of subjects: 98
Study 30614136 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group (WL)
Number of subjects: 98
Study 30614136 — intervention group
Group type: COMPARATOR
Intervention: Nondepressed age- and sex-matched controls
Number of subjects: 98
Study 28816894 — intervention group
Group type: EXPERIMENTAL
Intervention: ORIF (open reduction and internal fixation)
Number of subjects: 301
Study 28816894 — intervention group
Group type: COMPARATOR
Intervention: Nonoperative management
Number of subjects: 301
Study 25803435 — intervention group
Group type: COMPARATOR
Intervention: Lightwand only
Number of subjects: 90
Study 25803435 — intervention group
Group type: COMPARATOR
Intervention: Lightwand under direct laryngoscopy
Number of subjects: 90
Study 25803435 — intervention group
Group type: EXPERIMENTAL
Intervention: Lightwand with WEI JET under direct laryngoscopy
Number of subjects: 90
Study 22893313 — intervention group
Group type: EXPERIMENTAL
Intervention: BU-rATG (n = 69)
Number of subjects: 139
Study 22893313 — intervention group
Group type: COMPARATOR
Intervention: TBI (n = 70)
Number of subjects: 139
Study 22893313 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 139
Study 21191122 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive frame
Number of subjects: 298
Study 21191122 — intervention group
Group type: COMPARATOR
Intervention: Negative frame
Number of subjects: 298
Study 21191122 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined frame
Number of subjects: 298
Study 21191122 — intervention group
Group type: EXPERIMENTAL
Intervention: Percentage format
Number of subjects: 298
Study 21191122 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency format
Number of subjects: 298
Study 21191122 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly numerate participants
Number of subjects: 298
Study 22029560 — intervention group
Group type: EXPERIMENTAL
Intervention: Step dance sessions of 50 min per day, 3 days per week for 10 weeks with 60‐80% of heart rate reserves
Number of subjects: 138
Study 22029560 — intervention group
Group type: COMPARATOR
Intervention: Lecture control group (no organized or structured exercise)
Number of subjects: 138
Study 22029560 — intervention group
Group type: EXPERIMENTAL
Intervention: Step dance sessions
Number of subjects: 138
Study 17101405 — intervention group
Group type: EXPERIMENTAL
Intervention: SPIO-enhanced T(2)-weighted MRI
Number of subjects: 32
Study 17101405 — intervention group
Group type: COMPARATOR
Intervention: unenhanced T(2)-weighted MRI
Number of subjects: 32
Study 15003745 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenic training (AT) for 2 months, weekly sessions
Number of subjects: 31
Study 15003745 — intervention group
Group type: COMPARATOR
Intervention: Home visit only
Number of subjects: 31
Study 11674983 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 70
Study 11674983 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 70
Study 9566819 — intervention group
Group type: EXPERIMENTAL
Intervention: a‐interferon (10 million units then 5 million units three times weekly for 6 to 12 months)
Number of subjects: 410
Study 9566819 — intervention group
Group type: EXPERIMENTAL
Intervention: a‐interferon
Number of subjects: 410
Study 9566819 — intervention group
Group type: COMPARATOR
Intervention: relapsers/non-responders
Number of subjects: 410
Study 7771262 — intervention group
Group type: EXPERIMENTAL
Intervention: Gliclazide
Number of subjects: 0
Study 7771262 — intervention group
Group type: COMPARATOR
Intervention: Other sulphonylureas or placebo
Number of subjects: 0
Study 3338249 — intervention group
Group type: EXPERIMENTAL
Intervention: Large protein load (1.35 g/kg)
Number of subjects: 37
Study 3338249 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate protein load (1.08 g/kg)
Number of subjects: 37
Study 3338249 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild protein load (0.55 g/kg)
Number of subjects: 37
Study 3338249 — intervention group
Group type: COMPARATOR
Intervention: Control (carbohydrate meal)
Number of subjects: 37
Study 3338249 — intervention group
Group type: EXPERIMENTAL
Intervention: Large and moderate protein loads
Number of subjects: 37
Study 3338249 — intervention group
Group type: EXPERIMENTAL
Intervention: All protein loads
Number of subjects: 37
Study 29600568 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term rehabilitation programme
Number of subjects: 0
Study 29600568 — intervention group
Group type: EXPERIMENTAL
Intervention: Biopedagogies
Number of subjects: 0
Study 28558062 — intervention group
Group type: COMPARATOR
Intervention: AmBisome monotherapy (5 mg/kg single dose)
Number of subjects: 601
Study 28558062 — intervention group
Group type: EXPERIMENTAL
Intervention: AmBisome + paromomycin (5 mg/kg single dose + 10 days of paromomycin at 15 mg/kg/day)
Number of subjects: 601
Study 28558062 — intervention group
Group type: EXPERIMENTAL
Intervention: AmBisome + miltefosine (5 mg/kg single dose + 7 subsequent days of miltefosine at 2.5 mg/kg/day)
Number of subjects: 601
Study 28558062 — intervention group
Group type: EXPERIMENTAL
Intervention: Paromomycin + miltefosine (10 days of paromomycin at 15 mg/kg/day + miltefosine at 2.5 mg/kg/day)
Number of subjects: 601
Study 26201546 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive technology-assisted training and supervision program
Number of subjects: 434
Study 26201546 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 434
Study 23523641 — intervention group
Group type: EXPERIMENTAL
Intervention: TB treatment
Number of subjects: 385
Study 23523641 — intervention group
Group type: COMPARATOR
Intervention: Non-TB (control group)
Number of subjects: 385
Study 21751905 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol inhaler
Number of subjects: 39
Study 21751905 — intervention group
Group type: COMPARATOR
Intervention: Placebo inhaler
Number of subjects: 39
Study 21751905 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 39
Study 21751905 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 39
Study 18712479 — intervention group
Group type: EXPERIMENTAL
Intervention: NaP-45/45
Number of subjects: 121
Study 18712479 — intervention group
Group type: EXPERIMENTAL
Intervention: NaP-45/30
Number of subjects: 121
Study 18712479 — intervention group
Group type: COMPARATOR
Intervention: PEG-2L
Number of subjects: 121
Study 18712479 — intervention group
Group type: EXPERIMENTAL
Intervention: NaP-45/45, NaP-45/30, PEG-2L
Number of subjects: 121
Study 16820579 — intervention group
Group type: EXPERIMENTAL
Intervention: GIK (40% dextrose, K+ 100 mmol.L(‐1), insulin 70 u.L(‐1); 0.75 mL.kg(‐1).h(‐1) for 6 hours after aortic cross-clamp removal)
Number of subjects: 48
Study 16820579 — intervention group
Group type: EXPERIMENTAL
Intervention: GIK
Number of subjects: 48
Study 16820579 — intervention group
Group type: COMPARATOR
Intervention: Placebo (5% dextrose)
Number of subjects: 48
Study 15229965 — intervention group
Group type: EXPERIMENTAL
Intervention: human recombinant growth hormone (GH) for 6 months
Number of subjects: 25
Study 15229965 — intervention group
Group type: COMPARATOR
Intervention: placebo for 6 months
Number of subjects: 25
Study 11164716 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin-based chemotherapy
Number of subjects: 547
Study 9232301 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual midazolam 7.5 mg
Number of subjects: 100
Study 9232301 — intervention group
Group type: COMPARATOR
Intervention: Oral midazolam 7.5 mg
Number of subjects: 100
Study 7960816 — intervention group
Group type: EXPERIMENTAL
Intervention: Postnatal care following premature birth
Number of subjects: 0
Study 14591268 — intervention group
Group type: EXPERIMENTAL
Intervention: Formal memory remediation
Number of subjects: 20
Study 14591268 — intervention group
Group type: COMPARATOR
Intervention: Treatment focusing on psychosocial issues
Number of subjects: 20
Study 14591268 — intervention group
Group type: EXPERIMENTAL
Intervention: Subdivided groups based on severity of neuropsychological functioning
Number of subjects: 20
Study 29493708 — intervention group
Group type: EXPERIMENTAL
Intervention: Image‐guided Robotic Assisted Surgical simulator (IRAS) with robotic guidance
Number of subjects: 42
Study 28057452 — intervention group
Group type: EXPERIMENTAL
Intervention: Real tDCS
Number of subjects: 49
Study 28057452 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 49
Study 26970464 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG 0.1mg
Number of subjects: 281161
Study 26970464 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG 0.01mg
Number of subjects: 281161
Study 26970464 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 281161
Study 22843552 — intervention group
Group type: EXPERIMENTAL
Intervention: Indicator-guided puncture technique (PCK)
Number of subjects: 30
Study 22843552 — intervention group
Group type: COMPARATOR
Intervention: Standard surgical technique (ST)
Number of subjects: 30
Study 16724889 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week culturally targeted nutrition and physical activity intervention
Number of subjects: 366
Study 16724889 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 366
Study 14642938 — intervention group
Group type: EXPERIMENTAL
Intervention: STAN monitoring
Number of subjects: 173
Study 10888376 — intervention group
Group type: EXPERIMENTAL
Intervention: Anatomical approach (Group A)
Number of subjects: 43
Study 10888376 — intervention group
Group type: COMPARATOR
Intervention: Conventional approach (Group P)
Number of subjects: 43
Study 8545150 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sumatriptan (Imitrex, Glaxo)
Number of subjects: 7
Study 8545150 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 1975196 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaxolol 10 mg (B10)
Number of subjects: 6
Study 1975196 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaxolol 20 mg (B20)
Number of subjects: 6
Study 1975196 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaxolol 40 mg (B40)
Number of subjects: 6
Study 1975196 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaxolol 80 mg (B80)
Number of subjects: 6
Study 1975196 — intervention group
Group type: COMPARATOR
Intervention: Propranolol 40 mg (P40)
Number of subjects: 6
Study 1975196 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaxolol (all doses)
Number of subjects: 6
Study 6791563 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefaclor
Number of subjects: 110
Study 6791563 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin
Number of subjects: 110
Study 30056141 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS plus computerized cognitive training (CCT)
Number of subjects: 22
Study 30056141 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS plus CCT
Number of subjects: 22
Study 28610572 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal normal saline infusion with pulmonary recruitment maneuver (pressure of 40 cm H2O)
Number of subjects: 0
Study 28610572 — intervention group
Group type: COMPARATOR
Intervention: Control group with carbon dioxide removal through gentle abdominal pressure and passive exsufflation
Number of subjects: 0
Study 28610572 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal normal saline infusion with pulmonary recruitment maneuver
Number of subjects: 0
Study 28610572 — intervention group
Group type: COMPARATOR
Intervention: Control group with carbon dioxide removal
Number of subjects: 0
Study 26386749 — intervention group
Group type: EXPERIMENTAL
Intervention: Project Stride (equine-assisted activities and cognitive-behavioral strategies)
Number of subjects: 12
Study 26386749 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 12
Study 24074405 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-incision laparoscopic cholecystectomy (SILC)
Number of subjects: 100
Study 24074405 — intervention group
Group type: COMPARATOR
Intervention: Multi-incision laparoscopic cholecystectomy (MILC)
Number of subjects: 100
Study 20619577 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes-specific web-based 'Coping with Depression' (CWD) course; 8-lesson intervention with minimal guidance by coaches.
Number of subjects: 255
Study 17998306 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant pharmacotherapy in comparator trials
Number of subjects: 16
Study 17998306 — intervention group
Group type: COMPARATOR
Intervention: Antidepressant pharmacotherapy in placebo-controlled trials
Number of subjects: 16
Study 15689713 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN-alpha) administered intramuscularly at 9 x 10 IU daily for the first 4 weeks and then three times per week for the next 20 weeks.
Number of subjects: 98
Study 12804846 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 micrograms of yeast-derived recombinant hepatitis B vaccine (Heberbiovac HB)
Number of subjects: 0
Study 12804846 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 micrograms of yeast-derived recombinant hepatitis B vaccine (Heberbiovac HB)
Number of subjects: 0
Study 10098223 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/day
Number of subjects: 0
Study 10098223 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 120 mg/day
Number of subjects: 0
Study 10098223 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9010119 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant drugs (specific drugs not mentioned)
Number of subjects: 209
Study 9010119 — intervention group
Group type: COMPARATOR
Intervention: Excluded patients
Number of subjects: 209
Study 9010119 — intervention group
Group type: COMPARATOR
Intervention: Excluded patients with suicidal thoughts or intent
Number of subjects: 209
Study 1911582 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive companionship during labour
Number of subjects: 149
Study 7126388 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (2 to 16 mg)
Number of subjects: 20
Study 7126388 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol (10 to 80 mg)
Number of subjects: 20
Study 7126388 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 20
Study 7126388 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol
Number of subjects: 20
Study 31493477 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced Air Warming (FAW)
Number of subjects: 515
Study 31493477 — intervention group
Group type: COMPARATOR
Intervention: Resistive Fabric Warming (RFW)
Number of subjects: 515
Study 29237746 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitoring (756 patients)
Number of subjects: 1521
Study 29237746 — intervention group
Group type: COMPARATOR
Intervention: Usual care (765 patients)
Number of subjects: 1521
Study 23581606 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid silicone gel (LSG) applied to hypertrophic scars (HS group)
Number of subjects: 30
Study 23581606 — intervention group
Group type: COMPARATOR
Intervention: Silicone gel alone (control for HS group)
Number of subjects: 30
Study 23581606 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid silicone gel (LSG) applied to minor keloids (KS group)
Number of subjects: 30
Study 25065086 — intervention group
Group type: COMPARATOR
Intervention: Midazolam/meperidine
Number of subjects: 48
Study 25065086 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol infusion
Number of subjects: 48
Study 22931975 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane at various concentrations (0.2% to 3.4%) combined with remifentanil (1, 3, 6, and 10 ng/ml)
Number of subjects: 65
Study 22931975 — intervention group
Group type: COMPARATOR
Intervention: Remifentanil alone
Number of subjects: 65
Study 22931975 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane concentrations (1.04 ± 0.19)% to (1.81 ± 0.21)%
Number of subjects: 65
Study 22931975 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane and remifentanil combination
Number of subjects: 65
Study 19778675 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT)
Number of subjects: 80
Study 19778675 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT) with apical lead position
Number of subjects: 80
Study 19778675 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT) with midventricular lead position
Number of subjects: 80
Study 19778675 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT) with basal lead position
Number of subjects: 80
Study 19778675 — intervention group
Group type: COMPARATOR
Intervention: Normal subjects (control group)
Number of subjects: 80
Study 17519258 — intervention group
Group type: EXPERIMENTAL
Intervention: Active pulsed magnetic field therapy (PMFT) for 30 min (1.25 Hz, 3 ms width, 600 Gauss)
Number of subjects: 10
Study 17519258 — intervention group
Group type: COMPARATOR
Intervention: Sham pulsed magnetic field therapy (deactivated device) for 30 min
Number of subjects: 10
Study 15239219 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone 1 g once daily
Number of subjects: 902
Study 15239219 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (second‐generation cephalosporin, broad‐spectrum penicillin or a combination of aminopenicillin and beta‐lactamase inhibitor)
Number of subjects: 902
Study 11297956 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-lowering therapy
Number of subjects: 20709
Study 9875190 — intervention group
Group type: COMPARATOR
Intervention: Topical class 3 corticosteroids
Number of subjects: 63
Study 9875190 — intervention group
Group type: COMPARATOR
Intervention: Topical class 4 corticosteroids
Number of subjects: 63
Study 9875190 — intervention group
Group type: COMPARATOR
Intervention: Oral methoxsalen plus sunlight
Number of subjects: 63
Study 9875190 — intervention group
Group type: COMPARATOR
Intervention: Oral psoralen plus sunlight
Number of subjects: 63
Study 9875190 — intervention group
Group type: COMPARATOR
Intervention: Oral trioxsalen plus sunlight
Number of subjects: 63
Study 9875190 — intervention group
Group type: COMPARATOR
Intervention: Narrowband UV‐B
Number of subjects: 63
Study 9875190 — intervention group
Group type: COMPARATOR
Intervention: Broadband UV‐B
Number of subjects: 63
Study 9875190 — intervention group
Group type: COMPARATOR
Intervention: Oral methoxsalen plus UV‐A therapy
Number of subjects: 63
Study 7662616 — intervention group
Group type: EXPERIMENTAL
Intervention: Gelatin capsules coated with 20% w/v sodium alginate
Number of subjects: 0
Study 7662616 — intervention group
Group type: COMPARATOR
Intervention: Uncoated gelatin capsules
Number of subjects: 0
Study 2748113 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine treatment with Ocufen (flurbiprofen)
Number of subjects: 216
Study 2748113 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine treatment with Indocid (indomethacin)
Number of subjects: 216
Study 2748113 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine treatment alone
Number of subjects: 216
Study 2748113 — intervention group
Group type: COMPARATOR
Intervention: Ocufen (flurbiprofen) without epinephrine
Number of subjects: 216
Study 2748113 — intervention group
Group type: COMPARATOR
Intervention: Indocid (indomethacin) without epinephrine
Number of subjects: 216
Study 2748113 — intervention group
Group type: COMPARATOR
Intervention: Placebo without epinephrine
Number of subjects: 216
Study 2748113 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocufen + epinephrine
Number of subjects: 216
Study 2748113 — intervention group
Group type: COMPARATOR
Intervention: Indocin without epinephrine
Number of subjects: 216
Study 201786 — intervention group
Group type: EXPERIMENTAL
Intervention: Pivmecillinam 400 mg per day
Number of subjects: 0
Study 201786 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin 2000 mg per day
Number of subjects: 0
Study 31297659 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct technique
Number of subjects: 30
Study 31297659 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-direct technique
Number of subjects: 30
Study 30883766 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating VASPIN concentrations measured by ELISA
Number of subjects: 823
Study 30883766 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic variants in VASPIN
Number of subjects: 823
Study 30883766 — intervention group
Group type: EXPERIMENTAL
Intervention: Mendelian randomization analysis using VASPIN SNP
Number of subjects: 823
Study 28273285 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin monotherapy
Number of subjects: 2198
Study 28273285 — intervention group
Group type: COMPARATOR
Intervention: Heparin plus optional GPIs (control group)
Number of subjects: 2198
Study 25932481 — intervention group
Group type: EXPERIMENTAL
Intervention: Short Form-36
Number of subjects: 236
Study 25932481 — intervention group
Group type: EXPERIMENTAL
Intervention: CASP-19
Number of subjects: 236
Study 25932481 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Satisfaction Questionnaire-18
Number of subjects: 236